Changes in PROs can predict disease flares among patients with RA who discontinued csDMARD therapy after achieving sustained remission.

GLP-1 RAs are associated with a significant decrease in apnea-hypopnea index among patients with moderate to severe OSA and without diabetes.

The analysis of 3 dozen studies found similarities and differences in motivating factors for and against clinical trial ...

A study of more than 100 patients found that immunotherapy can cure a rare type of cancer in various tumor sites without ...

Results from a phase III clinical trial suggest that taking ubrogepant at the first sign of an oncoming migraine can prevent ...

In April 2025, Terns enrolled the first patient in the dose expansion portion of the Phase 1 CARDINAL study of TERN-701 for CML. Patients will be randomized to one of two dose cohorts (320 mg or 500 ...

Updated clinical data in heavily pre-treated, CAR-T naïve patients with B-NHL shows prolonged duration of response, with ...

"ABO21009 is the first antibody of its class to enter clinical trials in Europe and we believe it has great potential as a disease-modifying treatment for RA due to its multi-pronged ... material ...

For years, metformin has been the go-to first-line oral medication for patients newly diagnosed with type 2 diabetes. But ...

Medicaid enrollees with type 2 diabetes face restricted access to newer classes of first-line medications, especially in ...

Announced rosnilimab, a depleter and agonist targeting PD-1+ T cells, achieved positive results in Phase 2b rheumatoid arthritis (RA) trial; to present updated clinical and translational data in the ...

SAN DIEGO, May 05, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today reported financial ...